J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

By Michael Erman

Wed, July 15, 2026 astatine 5:27 AM CDT 2 min read

By Michael Erman

July 15 (Reuters) - Johnson & Johnson bushed Wall Street estimates for second-quarter income and nett connected Wednesday, arsenic beardown maturation from immunology cause Tremfya ‌and crab blockbuster Darzalex much than offset erosion from older products and ‌a driblet successful income for bosom pumps it picked up successful its 2022 acquisition of Abiomed.

J&J besides accrued ​its full-year income and nett forecast.

The healthcare conglomerate reported second-quarter income of $25.31 billion, up 6.6% from a twelvemonth earlier and supra analysts' mean estimation of astir $25.05 billion, according to LSEG data. Adjusted net were $2.90 per share, up 4.7% from a twelvemonth agone and topping expert expectations ‌of $2.85.

It present expects income of ⁠about $101.1 cardinal astatine the midpoint, from $100.8 cardinal previously. The institution besides raised its adjusted net per stock forecast to $11.68 astatine the midpoint, ⁠from $11.55 previously.

The institution said its pharmaceutical portion generated $16.38 cardinal successful quarterly sales, up of expert estimates of $16.1 billion.

Sales of its psoriasis and inflammatory bowel illness cause Tremfya roseate 72.5% to $2 billion, ​compared with ​LSEG estimates of $1.74 billion. Tremfya has go progressively ​important arsenic J&J works to regenerate ‌sales mislaid from Stelara, whose gross has fallen sharply aft losing its patent protection.

Second-quarter income of humor crab attraction Darzalex were $4.2 cardinal successful the quarter, astir successful enactment with expert estimates.

Sales astatine J&J's aesculapian exertion portion were $8.93 billion, somewhat trailing expert estimates.

CFO Joseph Wolk said successful an interrogation that Abiomed income successful the 4th were wounded aft work ‌of a U.K. survey that raised questions astir ​the usage of Impella pumps during definite high-risk coronary ​procedures. Abiomed income successful the 4th ​fell 2% twelvemonth implicit year, compared with 14% maturation successful the ‌first quarter.

He said J&J expects the franchise ​to instrumentality to growth, ​particularly arsenic the institution releases much information showing the inferior of the pumps.

"We person a large information acceptable coming retired astir apt successful the archetypal fractional of ​next twelvemonth that should allay ‌any fears," Wolk said. "When you person 28 platforms that make astatine slightest $1 ​billion successful gross connected an yearly basis, we're not babelike connected 1 asset."

(Reporting ​by Michael Erman; Editing by David Gregorio)